Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 46
- Registration Number
- NCT01339156
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
- Conditions
- Breast Cancer
- Interventions
- Drug: P276-00 along with Gemcitabine and carboplatin
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 11
- Registration Number
- NCT01333137
- Locations
- 🇺🇸
Disney Cancer Center, Burbank, California, United States
🇺🇸3855 Health Sciences Drive, La Jolla, California, United States
🇺🇸Washington University, St. Louis, Missouri, United States
Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Radiation: External beam radiotherapy (EBRT)
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 23
- Registration Number
- NCT00899054
- Locations
- 🇮🇳
Bhagwan Mahawir Cancer Hospital & Research Centre, Jaipur, Rajasthan, India
🇮🇳Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
🇮🇳Curie Manavata Cancer Center, Nashik, Maharashtra, India
Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 23
- Registration Number
- NCT00898287
- Locations
- 🇮🇳
Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India
🇮🇳Global Hospital, Hyderabaad, Andhra Pradesh, India
🇮🇳Curie Manavata Cancer Centre, Nashik, Maharashtra, India
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 19
- Registration Number
- NCT00882063
- Locations
- 🇮🇳
Shatabdi Superspeciality Hospital, Nasik, Maharashtra, India
🇮🇳Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India
🇮🇳Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 13
- Registration Number
- NCT00843050
- Locations
- 🇺🇸
Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Arizona, Scottsdale, Arizona, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇮🇳Malabar Institute of Medical Sciences, Calicut, Kerala, India
A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies
- Conditions
- Solid TumorHematologic Malignancy
- Interventions
- Drug: P1446A-05
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 29
- Registration Number
- NCT00840190
- Locations
- 🇮🇳
SEAROC Cancer Centre,, Jaipur, Rajasthan, India
🇮🇳Tata Memorial Centre, Mumbai, Maharashtra, India
🇮🇳Bhagwan Mahaveer Cancer Hospital, Jaipur, Rajasthan, India
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 12
- Registration Number
- NCT00835419
- Locations
- 🇮🇳
Curie Manavata Cancer Center, Nasik, Maharashtra, India
🇳🇿Christchurch Oncology Research Unit, Oncology Service, Christchurch Hospital, Riccarton Avenue, Private Bag 4710, Christchurch,, Christchurch, New Zealand
🇦🇺John Fawkner Cancer Trial Centre, Victoria, Australia
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 86
- Registration Number
- NCT00824343
- Locations
- 🇮🇳
Bhagwan Mahaveer Cancer Hospital & Research Centre, Dept. Of Medical Oncology, Jaipur, Jaipur, Rajasthan, India
🇮🇳Bharath Hospital & Institute of Oncology, Mysore, Mysore, Karnataka, India
🇮🇳Regional Cancer Centre, Trivandrum, Kerala, India
A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies
- Conditions
- Cancer
- Interventions
- Drug: P1446A-05
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 39
- Registration Number
- NCT00772876
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦London Health Sciences Centre (LHSC), London, Ontario, Canada
🇨🇦British Columbia Cancer Agency (BCCA),, Vancouver,, British Columbia, Canada